US EditionAward-winning Investigative News Program W5 Airs Part 2 of 3-part Television Series on Alleged Stock Market Manipulation of Quantum Biopharma Involving Two of Canada’s Largest Banks, CIBC and RBC
Quantum BioPharma alleges 16 million illegal orders on Canadian bank platforms in a $700 million lawsuit over stock spoofing targeting its shares.
- Yesterday, W5 aired Part Two of its three-part series on CTV News, examining alleged stock spoofing underpinning Quantum BioPharma's $700 million lawsuit against CIBC and RBC.
- Quantum alleges that at least 16 million illegal orders came from Canadian bank trading platforms, saying banks and brokers must act as gatekeepers to stop spoofing.
- As a biopharmaceutical, Quantum BioPharma Ltd. develops Lucid-MS and its subsidiary Lucid Psycheceuticals Inc. thanked W5 for investigating stock spoofing's harm to retail investors.
- Quantum BioPharma Ltd. cautioned that forward-looking statements involve risks and uncertainties, including legal proceedings and litigation funding plus whistleblower disclosures, and it undertakes no obligation to update them.
- As of September 30, 2025, Quantum BioPharma Ltd. retained 19.86% ownership of Unbuzzd Wellness Inc., with a 7% royalty until $250 million, dropping to 3% thereafter.
13 Articles
13 Articles
REPEAT: Award-winning Investigative News Program W5 Airs Part 2 of 3-part Television Series on Alleged Stock Market Manipulation of Quantum Biopharma Involving Two of Canada’s Largest Banks, CIBC and RBC
TORONTO, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma”), is pleased to announce that national television network CTV News’ flagship investigative program W5 has aired Part 2 of a three-part series…
REPEAT: Award-winning Investigative News Program W5 Airs Part 2 of 3-part Television Series on Alleged Stock Market Manipulation of Quantum Biopharma Involving Two of Canada’s Largest Banks, CIBC and RBC
TORONTO, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma”), is pleased to announce that national television network CTV News’ flagship investigative program W5 has aired Part 2 of a three-part series…
REPEAT: Award-winning Investigative News Program W5 Airs Part 2 of 3-part Television Series on Alleged Stock Market Manipulation of Quantum Biopharma Involving Two of Canada’s Largest Banks, CIBC and RBC
TORONTO, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma”), is pleased to announce that national television network CTV News’ flagship investigative program W5 has aired Part 2 of a three-part series…
REPEAT: Award-winning Investigative News Program W5 Airs Part 2 of 3-part Television Series on Alleged Stock Market Manipulation of Quantum Biopharma Involving Two of Canada’s Largest Banks, CIBC and RBC
TORONTO, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma”), is pleased to announce that national television network CTV News’ flagship investigative program W5 has aired Part 2 of a three-part series…
Award-winning Investigative News Program W5 Airs Part 2 of 3-part Television Series on Alleged Stock Market Manipulation of Quantum Biopharma Involving Two of Canada's Largest Banks, CIBC and RBC
TORONTO, Nov. 27, 2025 (GLOBE NEWSWIRE) — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“
Award-winning Investigative News Program W5 Airs Part 2 of 3-part Television Series on Alleged Stock Market Manipulation of Quantum Biopharma Involving Two of Canada’s Largest Banks, CIBC and RBC
TORONTO, Nov. 27, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma”), is pleased to announce that national television network CTV News’ flagship investigative program W5 has aired Part 2 of a three-part series…
Coverage Details
Bias Distribution
- 84% of the sources lean Left
Factuality
To view factuality data please Upgrade to Premium
